Supreme Court takes up generic drug labeling fight
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Aïda Amer/Axios
Supreme Court justices on Wednesday will hear arguments in a patent case that could change the way generic drug companies market and label copycat products.
Why it matters: At the heart of the case is whether efforts to lower health costs through generic competition are undercutting patent protections that brand-name drugmakers say are essential for innovation.
- It also exposes gray areas in the Hatch-Waxman Act, the Reagan-era law that lets drugmakers get approval to sell a generic for certain uses — called a "skinny label" — before all of the brand-name drug's patents expire.
Driving the news: Amarin Pharma is arguing that its patents were infringed when generic drugmaker Hikma Pharmaceuticals made a copycat version of a heart drug derived from fish oil and promoted it through press releases and marketing materials for a use still protected by patents.
- Justices will decide whether a drug labeled only for non-patented uses can still infringe on patents if the manufacturer induces doctors to prescribe it.
- An appeals court in 2024 found Amarin's allegations sufficient to make an infringement claim.
Between the lines: Legal experts say the case could clarify how far generics can go in marketing their products, and lay out what kind of evidence a brand-name drugmaker needs to demonstrate that a generic company actively encouraged doctors to prescribe a drug in a patented way.
- A ruling for Hikma could keep brand-name drugmakers' patent infringement cases from getting off the ground, even when the complaint relies on evidence like marketing statements to doctors, said Charles Collins-Chase, an attorney at IP litigation firm Finnegan.
- That could have a chilling effect on innovation, leaving brand-name manufacturers unable to protect new, patented uses and recover their investments in clinical studies, he said.
What they're saying: In legal filings, Amarin said it hasn't sued other generic companies but believes Hikma went further than the skinny label allows.
- Drug industry trade groups PhRMA and BIO jointly filed a brief supporting Amarin, saying Hikma is asking the court "to upend Congress's careful design and award them a special immunity from inducement liability," they wrote.
The other side: "The whole case is over affordability of prescription medicine," said John Murphy, CEO of the Association for Accessible Medicines, the generic drug lobby.
- A ruling that takes an "overly broad view" on induced patent infringement could make it too legally risky for generic drugmakers to enter certain markets, he said.
- That could let brand-name companies add new uses for an approved drug and never face generic competition, Murphy said.
The bottom line: The decision will reset the balance of generic competition and patent protection and how courts will interpret that balance in an era where drug marketing is under increased scrutiny, according to a Rothwell Figg analysis.
- It could also spur congressional efforts to carve out more safe harbors for makers of generics and biosimilars.
